Evotec SE 6-K, filed Mar 28, 2023
Evotec SE (EVO)
About this 6-K
Evotec SE filed this 6-K on March 28, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF MARCH 2023
COMMISSION FILE NUMBER 001-34041
| Evotec SE |
| (Translation of registrant’s name into English) |
Essener Bogen 7
22419 Hamburg
Germany
Tel: +49 40 560810
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐
On March 28, 2023, Evotec SE (the “Company”) announced that the Company has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb (NYSE:BMY), originally signed in 2016. The ad hoc release is attached hereto as Exhibit 99.1. An accompanying press release is attached hereto as Exhibit 99.2.
| 2 |
SIGNATURE
Pursuant to the requirements of s the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Evotec SE | |||
| By: | /s/ Enno Spillner | ||
|
|
| Name: Enno Spillner | |
| Title: Chief Financial Officer | |||
| Date: March 28, 2023 | |||
| 3 |
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership | |||||
| Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership |
| 4 |
EXHIBIT 99.1
28 March 2023
Ad hoc release according to Article 17 MAR of the Regulation (EU) No 596/2014
Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today that the Company has extended and expanded its strategic partnership with Bristol Myers Squibb (NYSE:BMY) in neurodegeneration, originally signed in 2016. Aim of the 8-year extension of the strategic alliance is to further broaden the programme pipeline in neurodegenerative diseases.
Evotec receives a $ 50 m upfront payment, undisclosed license and performance milestone payments, as well as tiered royalties up to low double-digit percentages on product sales. Including the upfront and downstream performance milestone payments, the overall transaction results in a deal potential of $ 4 bn.
– End of ad hoc release –
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, werner.lanthaler@evotec.com
EXHIBIT 99.2
